Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology)

Petar M. Seferovic; Gabriele Fragasso; Mark Petrie; Wilfried Mullens; Roberto Ferrari; Thomas Thum; Johann Bauersachs; Stefan D. Anker; Robin Ray; Yuksel Cavusoglu; Marija Polovina; Marco Metra; Giuseppe Ambrosio; Krishna Prasad; Jelena Seferovic; Pardeep S. Jhund; Giuseppe Dattilo; Jelena Celutkiene; Massimo Piepoli; Brenda Moura; Ovidiu Chioncel; Tuvia Ben Gal; Stephane Heymans; Tiny Jaarsma; Loreena Hill; Yuri Lopatin; Alexander R. Lyon; Piotr Ponikowski; Mitja Lainscak; Ewa Jankowska; Christian Mueller; Francesco Cosentino; Lars H. Lund; Gerasimos S. Filippatos; Frank Ruschitzka; Andrew J. S. Coats; Giuseppe M. C. Rosano

doi:10.1002/ejhf.2026

Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology)

Petar M. Seferovic^*, Gabriele Fragasso, Mark Petrie, Wilfried Mullens, Roberto Ferrari, Thomas Thum, Johann Bauersachs, Stefan D. Anker, Robin Ray, Yuksel Cavusoglu, Marija Polovina, Marco Metra, Giuseppe Ambrosio, Krishna Prasad, Jelena Seferovic, Pardeep S. Jhund, Giuseppe Dattilo, Jelena Celutkiene, Massimo Piepoli, Brenda MouraOvidiu Chioncel, Tuvia Ben Gal, Stephane Heymans, Tiny Jaarsma, Loreena Hill, Yuri Lopatin, Alexander R. Lyon, Piotr Ponikowski, Mitja Lainscak, Ewa Jankowska, Christian Mueller, Francesco Cosentino, Lars H. Lund, Gerasimos S. Filippatos, Frank Ruschitzka, Andrew J. S. Coats, Giuseppe M. C. Rosano

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium-glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given:

center dot Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin have consistently demonstrated to be effective for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. The specifically listed agents are recommended.

center dot Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction, already receiving guideline-directed medical therapy, regardless of the presence of type 2 diabetes mellitus.

Original language	English
Pages (from-to)	1984-1986
Number of pages	3
Journal	European journal of heart failure
Volume	22
Issue number	11
Early online date	27 Oct 2020
DOIs	https://doi.org/10.1002/ejhf.2026
Publication status	Published - Nov 2020

Keywords

Heart failure
Sodium&#8211
glucose co&#8208
transporter 2 inhibitors
Type 2 diabetes mellitus
Cardiovascular outcomes
Renal function

Access to Document

10.1002/ejhf.2026

Cite this

Seferovic, P. M., Fragasso, G., Petrie, M., Mullens, W., Ferrari, R., Thum, T., Bauersachs, J., Anker, S. D., Ray, R., Cavusoglu, Y., Polovina, M., Metra, M., Ambrosio, G., Prasad, K., Seferovic, J., Jhund, P. S., Dattilo, G., Celutkiene, J., Piepoli, M., ... Rosano, G. M. C. (2020). Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology). European journal of heart failure, 22(11), 1984-1986. https://doi.org/10.1002/ejhf.2026

Seferovic, Petar M. ; Fragasso, Gabriele ; Petrie, Mark et al. / Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure : beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology). In: European journal of heart failure. 2020 ; Vol. 22, No. 11. pp. 1984-1986.

@article{b80257a5d0474b66946b8c45b3582d97,

title = "Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology)",

abstract = "The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium-glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given:center dot Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin have consistently demonstrated to be effective for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. The specifically listed agents are recommended.center dot Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction, already receiving guideline-directed medical therapy, regardless of the presence of type 2 diabetes mellitus.",

keywords = "Heart failure, Sodium&#8211, glucose co&#8208, transporter 2 inhibitors, Type 2 diabetes mellitus, Cardiovascular outcomes, Renal function",

author = "Seferovic, {Petar M.} and Gabriele Fragasso and Mark Petrie and Wilfried Mullens and Roberto Ferrari and Thomas Thum and Johann Bauersachs and Anker, {Stefan D.} and Robin Ray and Yuksel Cavusoglu and Marija Polovina and Marco Metra and Giuseppe Ambrosio and Krishna Prasad and Jelena Seferovic and Jhund, {Pardeep S.} and Giuseppe Dattilo and Jelena Celutkiene and Massimo Piepoli and Brenda Moura and Ovidiu Chioncel and {Ben Gal}, Tuvia and Stephane Heymans and Tiny Jaarsma and Loreena Hill and Yuri Lopatin and Lyon, {Alexander R.} and Piotr Ponikowski and Mitja Lainscak and Ewa Jankowska and Christian Mueller and Francesco Cosentino and Lund, {Lars H.} and Filippatos, {Gerasimos S.} and Frank Ruschitzka and Coats, {Andrew J. S.} and Rosano, {Giuseppe M. C.}",

year = "2020",

month = nov,

doi = "10.1002/ejhf.2026",

language = "English",

volume = "22",

pages = "1984--1986",

journal = "European journal of heart failure",

issn = "1388-9842",

publisher = "Wiley",

number = "11",

}

Seferovic, PM, Fragasso, G, Petrie, M, Mullens, W, Ferrari, R, Thum, T, Bauersachs, J, Anker, SD, Ray, R, Cavusoglu, Y, Polovina, M, Metra, M, Ambrosio, G, Prasad, K, Seferovic, J, Jhund, PS, Dattilo, G, Celutkiene, J, Piepoli, M, Moura, B, Chioncel, O, Ben Gal, T, Heymans, S, Jaarsma, T, Hill, L, Lopatin, Y, Lyon, AR, Ponikowski, P, Lainscak, M, Jankowska, E, Mueller, C, Cosentino, F, Lund, LH, Filippatos, GS, Ruschitzka, F, Coats, AJS & Rosano, GMC 2020, 'Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology)', European journal of heart failure, vol. 22, no. 11, pp. 1984-1986. https://doi.org/10.1002/ejhf.2026

Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology). / Seferovic, Petar M.; Fragasso, Gabriele; Petrie, Mark et al.
In: European journal of heart failure, Vol. 22, No. 11, 11.2020, p. 1984-1986.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure

T2 - beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology)

AU - Seferovic, Petar M.

AU - Fragasso, Gabriele

AU - Petrie, Mark

AU - Mullens, Wilfried

AU - Ferrari, Roberto

AU - Thum, Thomas

AU - Bauersachs, Johann

AU - Anker, Stefan D.

AU - Ray, Robin

AU - Cavusoglu, Yuksel

AU - Polovina, Marija

AU - Metra, Marco

AU - Ambrosio, Giuseppe

AU - Prasad, Krishna

AU - Seferovic, Jelena

AU - Jhund, Pardeep S.

AU - Dattilo, Giuseppe

AU - Celutkiene, Jelena

AU - Piepoli, Massimo

AU - Moura, Brenda

AU - Chioncel, Ovidiu

AU - Ben Gal, Tuvia

AU - Heymans, Stephane

AU - Jaarsma, Tiny

AU - Hill, Loreena

AU - Lopatin, Yuri

AU - Lyon, Alexander R.

AU - Ponikowski, Piotr

AU - Lainscak, Mitja

AU - Jankowska, Ewa

AU - Mueller, Christian

AU - Cosentino, Francesco

AU - Lund, Lars H.

AU - Filippatos, Gerasimos S.

AU - Ruschitzka, Frank

AU - Coats, Andrew J. S.

AU - Rosano, Giuseppe M. C.

PY - 2020/11

Y1 - 2020/11

N2 - The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium-glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given:center dot Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin have consistently demonstrated to be effective for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. The specifically listed agents are recommended.center dot Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction, already receiving guideline-directed medical therapy, regardless of the presence of type 2 diabetes mellitus.

AB - The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium-glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given:center dot Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin have consistently demonstrated to be effective for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. The specifically listed agents are recommended.center dot Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction, already receiving guideline-directed medical therapy, regardless of the presence of type 2 diabetes mellitus.

KW - Heart failure

KW - Sodium&#8211

KW - glucose co&#8208

KW - transporter 2 inhibitors

KW - Type 2 diabetes mellitus

KW - Cardiovascular outcomes

KW - Renal function

U2 - 10.1002/ejhf.2026

DO - 10.1002/ejhf.2026

M3 - Article

C2 - 33068051

SN - 1388-9842

VL - 22

SP - 1984

EP - 1986

JO - European journal of heart failure

JF - European journal of heart failure

IS - 11

ER -

Seferovic PM, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T et al. Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology). European journal of heart failure. 2020 Nov;22(11):1984-1986. Epub 2020 Oct 27. doi: 10.1002/ejhf.2026